World stroke leaders meet at inaugural Clot Summit 2015


The world’s first Clot Summit has been held in Heidelberg, Germany. The meeting was chaired by Werner Hacke, a senior professor of Neurology at the University of Heidelberg Medical School.

Attending the meeting were clinicians from 12 countries, many of whom had played leadership roles in recent positive trials investigating endovascular scope therapy. Also in attendance were engineers and scientists focusing on various areas of research in clot and acute stroke.


The purpose of this interdisciplinary meeting was to identify ways to further advance the field of stroke therapy and improve patient care, with a main focus on ischaemic stroke. The summit’s design emphasised collaboration from clinicians, academics and engineers. 

“This gathering of experts provided a valuable exchange of ideas and knowledge, and I am grateful for the opportunity to learn from respected colleagues in the field,” says Hacke. “The summit was well received, with attendees expressing interest in further interdisciplinary research on clot to improve stroke intervention and patient outcomes.”  

During the summit, Neuravi presented insights gained from five years of the company’s research on the mechanical characteristics of clot and acute stroke occlusion dynamics.  

“Understanding the science of occlusions is fundamental to Neuravi’s interest in advancing stroke therapy, and having the opportunity to collaborate with a diverse group of experts greatly enriches the process of discovery and learning. We are delighted with the success of the inaugural Clot Summit,” says Eamon Brady, CEO of Neuravi. “Through the Neuravi Thromboembolic Initiative (NTI), we will continue to pursue research, facilitate discussions, and build collaborations to deepen the understanding of the role of clot in acute stroke.”

Thrombectomy has been proven as the best treatment for large vessel occlusive stroke, and now it is time to better understand clot in order to further advance care. This summit has contributed greatly to that discussion,” says Diederik Dippel, senior consultant in the Department of Neurology at the Erasmus Medical Center in Rotterdam, the Netherlands and lead investigator of the MR CLEAN trial.

Raul Nogueira director of Neuroendovascular Service and Neurocritical Care at Grady Memorial Hospital in Atlanta, Georgia, also recognised the need for better clot science.  “It is up to us to continue to push the envelope to further improve stroke care so that even more patients will benefit. I strongly believe that one of the best ways to do this is to build a better understanding of clot and occlusions.”